Compositions and methods for modulating ACE2 receptor
OwnerKamal Khan Mubarak, Eman Azra Mubarakinventors
Life of this patent
Estimating the term…
Abstract
Disclosed in certain embodiments are compositions and methods for treating coronavirus related adverse events with an angiotensin-converting enzyme 2 (ACE2) receptor modulator.
Claims6
A method of treating coronavirus related adverse events comprising administering to a patient in need thereof a therapeutically effective amount of an angiotensin-converting enzyme 2 (ACE2) receptor inhibitor,
- wherein the ACE2 receptor inhibitor modulator is hydroxyzine, cetirizine, azelastine, fexofenadine, loratadine, diphenhydramine, chloropheniramine, bromopheniramine, olopatadine, ketotifen, famotidine, cimetidine, ranitidine, clemastine, desloratadine, rupatadine, carbinoxamine, triprolidine, astemizole, levocabastine, bepotasine, ebastine, nizatidine, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, pharmaceutically acceptable salts thereof, or combinations thereof;
- wherein the coronavirus related adverse events are pulmonary, cardiac, dermatologic, gastrointestinal, renal, hepatic, endocrine, neurological, or a combination thereof;
- and
- wherein the ACE2 receptor inhibitor is administered by route comprising oral, intravenous, nasal, inhalational, topical, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intratrachael, otic, intraocular, or intrathecal route.
A method of treating coronavirus related adverse events comprising administering to a patient in need thereof a therapeutically effective amount of an angiotensin-converting enzyme 2 (ACE2) receptor inhibitor,
- wherein the ACE2 receptor inhibitor modulator is hydroxyzine, cetirizine, azelastine, fexofenadine, loratadine, diphenhydramine, chloropheniramine, bromopheniramine, olopatadine, ketotifen, famotidine, cimetidine, ranitidine, clemastine, desloratadine, rupatadine, carbinoxamine, triprolidine, astemizole, levocabastine, bepotasine, ebastine, nizatidine, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, pharmaceutically acceptable salts thereof, or combinations thereof;
- wherein the coronavirus related adverse events are pulmonary, cardiac, dermatologic, gastrointestinal, renal, hepatic, endocrine, neurological, or a combination thereof;
- and
- wherein the ACE2 receptor inhibitor is administered via a pulmonary route.
A method of treating coronavirus related adverse events comprising administering to a patient in need thereof a therapeutically effective amount of an angiotensin-converting enzyme 2 (ACE2) receptor inhibitor,
- wherein the ACE2 receptor inhibitor modulator is hydroxyzine, cetirizine, azelastine, fexofenadine, loratadine, diphenhydramine, chloropheniramine, bromopheniramine, olopatadine, ketotifen, famotidine, cimetidine, ranitidine, clemastine, desloratadine, rupatadine, carbinoxamine, triprolidine, astemizole, levocabastine, bepotasine, ebastine, nizatidine, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, pharmaceutically acceptable salts thereof, or combinations thereof;
- wherein the coronavirus related adverse events are pulmonary, cardiac, dermatologic, gastrointestinal, renal, hepatic, endocrine, neurological, or a combination thereof;
- and
- wherein the ACE2 receptor inhibitor is administered by route comprising oral, intravenous, nasal, inhalational, topical, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intratrachael, otic, intraocular, or intrathecal route;
- provided that the ACE2 receptor inhibitor is permeable to the blood brain barrier.
Dependencies are inferred from the claim text.